Acrivon (ACRV) CEO Peter Blume-Jensen Sells Shares

What Happened
Peter Blume-Jensen, President & CEO and a director of Acrivon Therapeutics (ACRV), disposed of a total of 1,713 shares in two transactions on August 18, 2026. The sales were: 1,229 shares at $2.01 ($2,470) and 484 shares at $2.01 ($973), totaling $3,443. The filing indicates these sales were to satisfy mandatory tax withholding upon vesting of restricted stock units (RSUs), so they are routine tax-withholding disposals rather than discretionary stock sales.

Key Details

• Transaction date: 2026-08-18; Filing date: 2026-08-20 (timely filing).
• Trades: 1,229 shares @ $2.01 ($2,470) and 484 shares @ $2.01 ($973); total 1,713 shares for $3,443.
• Transaction code: S = Sale; footnote F1 = automatic sale to cover tax withholding on RSU vesting.
• Footnotes F2 & F3 note certain securities are held by the CEO's spouse and the EVP/spouse disclaims beneficial ownership except for pecuniary interest.
• Shares owned after the transaction are not specified in the provided excerpt of the Form 4.

Context
These disposals were tax-withholding sales tied to RSU vesting (per footnote), which is a common, non-informational insider transaction. For retail investors, such sales generally do not signal management's view on company prospects in the same way a voluntary open-market sale might.